CEFYBO   02669
CENTRO DE ESTUDIOS FARMACOLOGICOS Y BOTANICOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Maternal treatments to prevent diabetic embryopathy
Autor/es:
ROMINA HIGA
Lugar:
Puerto Varas
Reunión:
Congreso; VII SLIMP Latin American Symposium on Maternal Fetal Interaction and Placenta; 2017
Institución organizadora:
SLIMP
Resumen:
Maternal diabetes induces alterations in embryo development and increases resorption and malformation rates. The pro-oxidant/pro-inflammatory intrauterine environment is clearly an important factor involved in the induction of diabetic embryopathy. We focus on the study of maternal treatments able to protect and prevent impaired embryo development.The antioxidant idebenone, a structural analog of coenzyme Q10 with potent effects as antioxidant, ameliorates the altered parameters related to a pro-oxidant/pro-inflammatory environment, improve mitochondrial function and biogenesis and prevents apoptosis in embryos from mild diabetic rats. Also related to its antioxidant and anti-inflammatory properties, unsaturated fatty acids that activate the nuclear receptors PPARs can be dietary administered to mothers during pregnancy. PPARdelta is the only PPAR isoform expressed in the embryo during early organogenesis. PPARdelta expression, the levels of other components of the PPAR system, and PPARdelta-regulated genes such as matrix metalloproteinases (MMPs, involved in tissue remodeling) are altered in embryos from diabetic rats. Olive oil (oleic acid-enriched, PPAR activator) supplementation in the maternal diet modulates the expression of components of the PPAR system and the activity of MMPs. Also folic acid and safflower oil (linoleic acid-enriched, PPAR activator) supplementation prevent embryo malformations in diabetic rats, acting through the modulation of reactive oxygen species, prostacyclin (PPARdelta endogenous activator) and nitric oxide (embryo morphogen) production and the regulation of MMPs and their endogenous inhibitors.Our results show the capacity of maternal treatments with antioxidants and/or PPAR agonists to improve embryo development and prevent embryo resorptions and malformations in diabetes and pregnancy experimental models.